Cy­to­Dyn fires em­bat­tled CEO as its grow­ing cho­rus of crit­ics gets loud­er

Among the many biotechs and phar­mas pitch­ing their cor­ner­stone drugs as po­ten­tial cures for Covid-19, few have earned as ig­no­min­ious a rep­u­ta­tion as Cy­to­Dyn. Fac­ing mount­ing crit­i­cism — and a cou­ple of probes, for good mea­sure — Cy­to­Dyn is now dump­ing its long­stand­ing CEO in a Hail Mary at­tempt to re­ha­bil­i­tate its im­age.

Cy­to­Dyn has fired CEO Nad­er Pourhas­san, the ex­ec­u­tive re­spon­si­ble for guid­ing the dis­as­trous R&D ef­fort and PR cam­paign for leron­limab, an in­ves­ti­ga­tion­al drug the com­pa­ny has pitched as a po­ten­tial ther­a­py for can­cer, Covid-19 and HIV, the biotech said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER